Lifecore rises as new manufacturing deal supports growth outlook

Shares of drug contract manufacturer Lifecore Biomedical LFCR.O rise 1.4% to $4.07 premarket

Co says it signed a manufacturing agreement with a new customer in the aesthetics market

Deal involves taking over U.S. production of an already‑approved sterile injectable drug currently made outside the United States, co says

Says the transfer should boost supply for the U.S. market and adds to its commercial‑stage portfolio

Lifecore expects the program to generate commercial revenue within 24 months

Deal supports co’s target of about 12% average annual revenue growth through 2029, co says

This is co’s third commercial site‑transfer deal in about five months - LFCR

Shares up ~10% in 2025